Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Worldwide, there are nearly 10 million new cases of dementia annually, of which
Alzheimer's disease (AD) is the most common. New measures are needed to improve the …

Aducanumab has been approved by the US Food and Drug Administration for treatment of
Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new …

Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing
plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic …

Alzheimer Disease - StatPearls - NCBI Bookshelf US flag An official website of the United
States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …

Neurodegenerative diseases are the most common cause of dementia. Although their
underlying molecular pathologies have been identified, there is substantial heterogeneity in …

PURPOSE OF REVIEW This article summarizes the cognitive and behavioral functions of
the prefrontal cortex with an emphasis on executive cognitive functions and the clinical …

The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …